{"id":"W2794945244","doi":"10.1016/j.lungcan.2018.03.025","title":"Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting","year":2018,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Eli Lilly and Company","keywords":"Medicine; Oncology; Docetaxel; Internal medicine; Bevacizumab; Ramucirumab; Lung cancer; Nintedanib; Refractory (planetary science); Chemotherapy; Lung; Idiopathic pulmonary fibrosis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001498792,0.0006683829,0.001363194,0.0002039847,0.0001988186,0.00004514569,0.0003133945,0.0002736326,0.0006444003],"category_scores_gemma":[0.00002375743,0.0003382952,0.0004202219,0.0005186304,0.00007297489,0.0001226935,0.0000343807,0.0003953007,0.000004348377],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001087304,"about_ca_system_score_gemma":0.002558297,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001717805,"about_ca_topic_score_gemma":0.001429683,"domain_scores_codex":[0.9975472,0.00009362288,0.0006339252,0.0007778582,0.000332468,0.0006149172],"domain_scores_gemma":[0.9975331,0.000299111,0.001075383,0.0006353323,0.0003368365,0.0001201919],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001055607,0.0007565594,0.007328996,0.03196022,0.003214287,0.00008066723,0.002860163,0.00001723577,0.000002923555,0.000002001665,0.0142901,0.9384313],"study_design_scores_gemma":[0.008081618,0.0009968415,0.001035097,0.03415545,0.005024564,0.000008878369,0.00009311466,0.0000577164,0.00001541933,0.000001561048,0.9499449,0.0005849144],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.005497033,0.9825032,0.0000388515,0.0001058491,0.0007888542,0.0088733,0.001742051,0.00003744233,0.0004134574],"genre_scores_gemma":[0.0007198915,0.9825436,0.0005388483,0.0007381599,0.0009886442,0.008498965,0.0007707047,0.0001954842,0.005005716],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9378463,"threshold_uncertainty_score":0.9999069,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0180276582502401,"score_gpt":0.3736487933526319,"score_spread":0.3556211351023918,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}